Articles by Tyler Menichiello

  1. Gene Therapy CMC Experts On Late-Stage Process Changes 9/27/2024

    At the 2024 Bioprocessing Summit, a panel of CMC experts spoke about the challenges commercializing gene therapies, specifically focusing on considerations for late-stage process changes.

  2. The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement 9/12/2024

    Experts from last month's Cell & Gene Live event discuss the innovations seen in CAR-T manufacturing and shared their thoughts on the feasibility of decentralized and point-of-care models to address manufacturing challenges.

  3. Key Takeaways From The 2024 Bioprocessing Summit 8/26/2024

    Editor Tyler Menichiello reflects on the topics and trends covered at this year's Bioprocessing Summit in Boston.

  4. A Call To Re-Evaluate Islet-Cell Regulations 8/15/2024

    Autologous islet cell transplantation (AIT) is regulated differently than allogeneic islet cell transplantation, which requires a BLA. Imagine Pharma's Dr. Rita Bottino makes the case for changing these regulations to better serve patients with Type 1 diabetes.

  5. Integrating Analytics And Automation In Cell Therapy Manufacturing 7/31/2024

    Experts from last month’s Cell & Gene Live event discuss practical ways to utilize emerging technologies.

  6. Manufacturing CAR-T In Vivo 7/25/2024

    Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.

  7. Rocket Pharma's Modality-Agnostic Approach To Rare Disease 7/24/2024

    Rocket Pharmaceuticals’ president, COO, and head of R&D, Dr. Kinnari Patel, discusses the company’s modality-agnostic approach to treating rare diseases.

  8. Building A Universal AAV For Cancer 6/28/2024

    "Universal" isn't the first word most people think of when they think about AAVs. But what if there were such a thing? Siren Biotechnology's CEO, Dr. Nicole Paulk, shares the story behind developing the company's universal AAV immuno-gene therapy.

  9. The Rising Tide Of Ophthalmologic Gene Therapies 6/27/2024

    There’s an explosion of clinical activity in the gene therapy space for inherited retinal diseases (IRDs). Atsena Therapeutics' CMO, Dr. Kenji Fujita, explains what makes IRDs such appealing gene therapy targets and shares the company’s strategic approach to clinical development.

  10. Using Stem Cells As An Immunologic 'Trojan Horse' 5/23/2024

    The immune system makes therapeutic delivery challenging, even for immunotherapies. Learn how Calidi Biotherapeutics is using stem cells to sneak oncolytic viruses past the immune system to the sites of solid tumors.